Predictive Oncology INC 8-K filings
Predictive Oncology Inc. has received a delisting notice from Nasdaq due to its failure to meet the minimum $2.5 million stockholders' equity requirement, though it has appealed the decision.
Predictive Oncology Inc. has filed a prospectus supplement to update its At-The-Market (ATM) offering program, adjusting the maximum aggregate offering price of common stock it is eligible to sell to $3.398 million as of June 2, 2025, while retaining a total program capacity of up to $4.889 million.
Predictive Oncology reported a loss from continuing operations of approximately $2.3 million on total revenue of $110,310 for the quarter ended March 31, 2025.
Predictive Oncology Inc. (POAI) has officially discontinued merger discussions with Renovaro Inc. (RENB) and clarifies that no binding merger agreement was ever established.
Predictive Oncology Inc. (POAI) announces the discontinuation of merger discussions with Renovaro Inc. (RENB) due to the termination of the letter of intent.
Predictive Oncology reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024, and is progressing towards a merger agreement with Renovaro.
Predictive Oncology divests its Skyline Medical assets, including the STREAMWAY product line, to DeRoyal Industries for $625,000 to focus on AI-driven drug discovery.
Predictive Oncology and Renovaro amend their merger agreement, extending the termination date and securing initial financing for integration efforts.
Predictive Oncology Inc. has successfully completed a registered direct offering, raising approximately $545,004 through the sale of common stock.
Predictive Oncology Inc. held its annual meeting on December 30, 2024, where stockholders elected two Class III directors, ratified the appointment of KPMG LLP as auditor, approved the 2024 Equity Incentive Plan, and did not approve the advisory resolution on executive compensation.
Predictive Oncology has entered a binding letter of intent to be acquired by Renovaro in a deal involving preferred stock, aiming to create scientific synergies and reduce operating costs.
Predictive Oncology Inc. received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement for continued listing.
Predictive Oncology reported a $2.3 million loss on $345,686 in revenue for Q3 2024 and has initiated a process to explore strategic alternatives to maximize shareholder value.
Predictive Oncology has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock price has remained below $1 for 30 consecutive days.
Predictive Oncology announced its second quarter 2024 financial results, highlighted by a strategic shift into biomarker discovery and a cost-saving initiative.
Predictive Oncology has successfully raised $1.26 million by incentivizing the exercise of existing warrants, while also issuing new warrants to the same holders.
Predictive Oncology's AI models demonstrated superior prediction of ovarian cancer patient survival compared to clinical data alone, according to a study conducted with UPMC Magee-Womens Hospital.
Predictive Oncology announced its first quarter 2024 financial results, reporting a net loss of $4.2 million on revenue of $0.4 million, while also highlighting advancements in AI-driven drug discovery and biologics capabilities.
Predictive Oncology Inc. has entered into an agreement with H.C. Wainwright & Co., LLC to sell up to $3.696 million of its common stock through an at-the-market offering program.
Predictive Oncology Inc. has engaged KPMG as its new independent auditor, replacing BDO, effective April 3, 2024.
Predictive Oncology reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023, while highlighting progress in key collaborations and AI-driven research.
Predictive Oncology has amended its previous 8-K filing to disclose the board's decision to hold annual Say-on-Pay votes, following shareholder preference expressed at the 2022 annual meeting.
Predictive Oncology's Chief Business Officer, Pamela Bush, Ph.D., MBA, will depart the company effective February 15, 2024, prompting a search for a replacement.